Zydus Lifesciences Announces Positive Topline Results From Phase II(b) Trial of Saroglitazar Mg in MASH

Zydus Reports Positive Results from EVIDENCES-X Phase II b Clinical Trial of Saroglitazar Mg in MASH

Ahmedabad, Aug 31: Zydus, an innovation-led global lifesciences company, today announced positive topline results from its completed EVIDENCES-X Phase IIb, prospective, multicentre, randomized, double-blind, placebo-controlled clinical trial evaluating the efficacy and safety of Saroglitazar Magnesium [...] The post Zydus Reports Positive Results from EVIDENCES-X Phase II b Clinical Trial of Saroglitazar Mg in MASH appeared first on Business New…

Zydus reports positive Phase II(b) EVIDENCES-X results for Saroglitazar Mg in MASH

Global trial met its primary endpoint of MASH resolution without worsening of fibrosis at week 52 The post Zydus reports positive Phase II(b) EVIDENCES-X results for Saroglitazar Mg in MASH appeared first on Express Pharma.

Zydus Lifesciences announces positive topline results from Phase II(b) trial of Saroglitazar Mg in MASH

Zydus Lifesciences has reported positive topline results from its completed EVIDENCES-X Phase II(b) clinical trial of Saroglitazar Mg in MASH. The outcome marks a significant milestone in the company's clinical development programme for the liver disease treatment candidate.

Zydus Announces Positive Topline Results from Completed EVIDENCES-X Phase II(b) Clinical Trial of Saroglitazar Mg in MASH

Zydus, a leading innovation-led global lifesciences company, today announced positive topline results from its completed EVIDENCES-X™ Phase II(b), prospective, multicentre, randomized, double-blind, placebo-controlled clinical trial evaluating the efficacy and safety of Saroglitazar Magnesium in patients with Metabolic dysfunction Associated Steatohepatitis (MASH) and fibrosis. The liver biopsy-driven EVIDENCES-X™ study enrolled 189 subjects who…